ANORO ELLIPTA CLINICAL TRIALS DATA
ANORO ELLIPTA (UMEC/VI»: [1], [2]) is a once-daily combination inhaler containing umeclidinium (a long-acting muscarinic antagonist or LAMA) and vilanterol (a long-acting beta2-adrenergic agonist or LABA). It is prescribed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1].
CLINICAL TRIALS SUPPORTING ANORO ELLIPTA
The efficacy and safety of ANORO ELLIPTA were established in multiple randomized, double-blind, placebo-controlled clinical trials [2]. Key studies included those involving over 7,000 patients with moderate to very severe COPD. These trials evaluated ANORO ELLIPTA against placebo and its individual components, umeclidinium and vilanterol, as well as against other bronchodilators [2].
Primary endpoints in these trials typically focused on improvements in trough forced expiratory volume in 1 second (FEV1) at different time points, often at 24 weeks or longer [2]. Secondary endpoints included assessments of COPD exacerbations, symptom scores, and health-related quality of life [2].
The trials demonstrated that ANORO ELLIPTA provided statistically significant improvements in lung function compared to placebo [2]. Furthermore, combination therapy with umeclidinium and vilanterol showed greater bronchodilation than either agent alone [2]. Studies also indicated a reduction in the rate of moderate to severe COPD exacerbations for patients using ANORO ELLIPTA compared to placebo [2].
ANORO ELLIPTA VS. OTHER COPD TREATMENTS
ANORO ELLIPTA is part of a broader landscape of COPD treatment options, including other long-acting bronchodilators and inhaled corticosteroids. Clinical trials have compared ANORO ELLIPTA to various monotherapies and combination therapies. For instance, studies have assessed ANORO ELLIPTA against tiotropium (a LAMA) and combinations of LABA/ICS. These comparative studies aim to define the role of ANORO ELLIPTA within the treatment algorithm for COPD, considering its efficacy in improving lung function and reducing exacerbations [2].
When considering ANORO ELLIPTA versus other bronchodilator combinations, the choice often depends on individual patient characteristics, symptom severity, exacerbation history, and physician preference [2].
HOW LONG DOES ANORO ELLIPTA TAKE TO WORK?
ANORO ELLIPTA begins to improve symptoms shortly after the first dose, with noticeable improvements in breathing occurring within minutes. However, to achieve the full bronchodilating effect and consistent symptom relief, regular daily use is necessary. The maintenance of these effects is established over time with continued treatment [1].
CLINICAL TRIAL RESULTS ON EXACERBATIONS
A significant aspect of ANORO ELLIPTA's clinical evaluation involved its impact on COPD exacerbations, which are critical events that significantly worsen the disease and can lead to hospitalization [2]. Several pivotal trials, including the ACT (Assessing Combination Therapy) studies, demonstrated that ANORO ELLIPTA significantly reduced the rate of moderate to severe COPD exacerbations compared to placebo [2]. This reduction in exacerbations is a key benefit for patients managing COPD.
SIDE EFFECTS OBSERVED IN CLINICAL TRIALS
The safety profile of ANORO ELLIPTA has been evaluated in extensive clinical trials [2]. Common side effects reported in clinical studies include nasopharyngitis (common cold symptoms), upper respiratory tract infection, constipation, diarrhea, pain in extremities, muscle spasms, chest pain, indigestion, and blurred vision [1]. Paradoxical bronchospasm, though rare, is a potential serious adverse event associated with all inhaled bronchodilators and requires immediate medical attention [1]. Cardiovascular events, such as palpitations and increased heart rate, have also been observed [2].
HOW DOES ANORO ELLIPTA WORK?
ANORO ELLIPTA utilizes a dual mechanism of action to treat COPD. Vilanterol, a LABA, works by relaxing the muscles around the airways, which helps to open the airways and improve airflow to the lungs [1]. Umeclidinium, a LAMA, also relaxes airway muscles by blocking the action of acetylcholine, a substance in the body that causes muscles to contract and airways to narrow [1]. By combining these two mechanisms, ANORO ELLIPTA provides a more sustained and comprehensive bronchodilation than either component alone [2].
SOURCES
1. DrugPatentWatch.com
2. DrugPatentWatch.com